This book examines the current status of mHealth development, regulations and the social background in Japan, South Korea and China, comparing it to the situation in the United States and the European Union and consider solutions to issues surrounding mHealth.
The recent progress in mobile technology, represented by smartphones and smart watches, has been remarkable. A service called mobile health (mHealth), which uses such mobile technology to manage health, is also becoming a reality. Although the accuracy of medical devices is not as accurate as those used in medicine, the biometric information such as heart rate and SpO2 can already be monitored over a long period of time. Although the technology is maturing to the point where it can be implemented in society, it remains an unapproved service of medical care in most countries. The development and social implementation of mHealth is most active in the US, but social implementation is gradually progressing in other countries as well. In this book, we will first discuss what kind of global and harmonized regulations are desirable by comparing the regulatory reforms necessary for social implementation of mHealth. In addition, mHealth raises privacy concerns in the US because the usual behavior and biometric information of subjects is utilized by private companies. In addition, it is important to note that the behavior and biometric information of subjects collected by smart devices is automatically analyzed by AI technology, mainly machine learning, which makes the analysis a black box.
|
Global Scale Comparison of mHealth Regulation |
|
|
|
Introduction of the Concept of AI in the Field of mHealth While Discovering the Trends in the mHealth Research Field |
|
|
3 | (28) |
|
|
|
|
|
|
|
Relationship of Innovation and Regulation on mHealth |
|
|
31 | (22) |
|
|
|
|
|
The Current Situation of Mobile Health in China from the Perspective of Policy, Application, User Acceptance: A Multi-Method Systematic Analysis |
|
|
53 | (30) |
|
|
|
|
|
Digital Healthcare Development and mHealth in South Korea |
|
|
83 | (34) |
|
|
|
|
|
Regulations and the Status of Social Implementation of Services on mHealth in Japan |
|
|
117 | (24) |
|
|
|
|
|
Precision Public Health and the Role of mHealth: The Use of Smartphone Applications Worldwide in Mitigating the COVID-19 Pandemic and Their Integration as Components of Public Health Policies. A Focus on the French Example |
|
|
141 | (34) |
|
|
|
|
|
Summary of the First Half and the Possibilities and Problems Related to mHealth in the Later
Chapters |
|
|
175 | (14) |
|
|
|
Discussion of mHealth Development with Case Studies |
|
|
|
mHealth as a Component of Next-Generation Health Care |
|
|
189 | (22) |
|
|
|
mHealth's Potential for Measuring Work Attitudes in Psychological and Physical Factors |
|
|
211 | (28) |
|
|
|
mHealth Beyond Healthcare-Fusion Approach Towards Better Wellness- |
|
|
239 | (14) |
|
|
|
Mobile Health for Preventive Healthcare |
|
|
253 | (20) |
|
|
|
|
|
273 | |
|
|
Dr. Kodama joined Suntory Holdings Limited after graduating (1998) and completed master's degree (2000) at Kyushu University Department of Pharmaceutical Sciences. He obtained a Ph.D. (Pharmaceutical Sciences) from Kyushu University in 2004. After predoctoral at RIKEN and postdoctoral training at several university, he contributed the industry-academic joint research at Hokkaido University as an associate professor and project manager (20102016). He has been appointed for an associate professor, Graduate School of Technology Management (MOT), Ritsumeikan University, since 2016 to present. He has been engaged in a variety of academic, business and projects management, especially in the field of life sciences. His areas of specialization are technology management, entrepreneurship, business development and bioinformatics. Recently, he is selected as Fellow of Fondation France-Japon de l'EHESS.
Prof. Dr. Shintaro Sengoku is Professor and Principal Investigator ofSchool of Environment and Society, Tokyo Institute of Technology and Visiting Professor of the Institute for Future Initiatives, the University of Tokyo. He has professional experience in advisory services at McKinsey&Company and Fast Track Initiative, Inc., a venture capital focusing on the bio/health technology industry; research and education experience in the field of management of technology and innovation research at Graduate School of Pharmaceutical Sciences, the University of Tokyo, International Collaborative Center, Kyoto University and Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University.
